Anthropic picks Twist Bioscience (NASDAQ: TWST) to test AI-designed proteins

Rhea-AI Filing Summary

Twist Bioscience Corporation (TWST) reported that Anthropic, PBC published a blog post describing results from a multi-arm protein design campaign against 15 targets using its Claude Opus 4.8 and Mythos Preview AI models. Anthropic selected Twist Bioscience as one of its independent evaluators to rapidly manufacture these AI-designed proteins at scale and test them for binding.

The disclosure is made under Regulation FD and is furnished, not filed, meaning it is not automatically incorporated into Twist Bioscience’s Securities Act filings unless specifically referenced there.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Key Figures

Protein design targets: 15 targets Disclosure date: August 18, 2026 Company telephone number: (800) 719-0671

3 metrics

Protein design targets 15 targets Number of targets in Anthropic's multi-arm protein design campaign

Disclosure date August 18, 2026 Date Anthropic's blog post and Twist's Regulation FD disclosure are referenced

Company telephone number (800) 719-0671 Twist Bioscience principal executive offices contact number

Key Terms

Regulation FD, multi-arm protein design campaign, independent evaluators, AI-designed proteins

4 terms

Regulation FD regulatory

"The information furnished in this Item 7.01 is being furnished under Regulation FD"

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

multi-arm protein design campaign medical

"received data back for a multi-arm protein design campaign against 15 targets"

independent evaluators technical

"chosen Twist Bioscience Corporation as one of its independent evaluators"

AI-designed proteins technical

"to rapidly produce at scale these AI-designed proteins and test these designs"

FAQ

What did Twist Bioscience (TWST) announce regarding Anthropic's protein design campaign?

Twist Bioscience announced that Anthropic selected it as one of several independent evaluators to manufacture AI-designed proteins and test them for binding from a multi-arm protein design campaign using Claude Opus 4.8 and Mythos Preview against 15 targets.

What role will Twist Bioscience (TWST) play in Anthropic's AI protein design work?

Twist Bioscience will act as an independent evaluator, rapidly producing at scale the AI-designed proteins generated in Anthropic’s campaign and testing these protein designs for binding, helping assess how well the designs perform experimentally.

Which AI models did Anthropic use in the protein design project involving TWST?

Anthropic used its Claude Opus 4.8 and Mythos Preview models for a multi-arm protein design campaign against 15 targets. Twist Bioscience was chosen to translate these model-generated protein designs into physical proteins and evaluate their binding properties.

Is the Anthropic-related disclosure by Twist Bioscience (TWST) considered filed with the SEC?

No. Twist states the information is furnished under Regulation FD, not “filed” under Section 18 of the Exchange Act, and is not incorporated into Securities Act registration statements unless specifically referenced, which limits associated liabilities and legal effects.

Where can investors read Anthropic's blog post mentioned by Twist Bioscience (TWST)?

Anthropic’s blog post is available at www.anthropic.com/research/Claude-accelerates-protein-design. Twist notes that information on or accessible through Anthropic’s website is not incorporated by reference into Twist’s securities filings unless expressly stated.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 08/19/2026 - 06:03 AM Accepted by SEC EDGAR 08/18/2026 - 06:15 PM Learn about SEC filing dates

FALSE000158128000015812802026-08-182026-08-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

August 18, 2026

Twist Bioscience Corporation

(Exact name of registrant as specified in its charter)

Delaware

001-38720

46-2058888

(State or other jurisdiction of incorporation)

(Commission File Number)

(I. R. S. Employer Identification No.)

681 Gateway Boulevard

South San Francisco, CA 94080

(Address of principal executive offices, including ZIP code)

(800) 719-0671

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock

TWST

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01     Regulation FD Disclosure.

On August 18, 2026, Anthropic, PBC (“Anthropic”) published a blog post announcing that it had received data back for a multi-arm protein design campaign against 15 targets using Claude Opus 4.8 and Mythos Preview, and that it had chosen Twist Bioscience Corporation (the “Company”) as one of its independent evaluators to rapidly produce at scale these AI-designed proteins and test these designs for binding. The blog post is available at www.anthropic.com/research/Claude-accelerates-protein-design . Information on or accessible through Anthropic’s website is not incorporated by reference in this Current Report on Form 8-K.

The information furnished in this Item 7.01 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 18, 2026			Twist Bioscience Corporation
			/s/ Judy Yan
			Judy Yan
			Assistant General Counsel and Assistant Secretary

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 21.1 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.2 KB